Current Rating and Its Significance
MarketsMOJO’s 'Hold' rating for Shilpa Medicare Ltd indicates a neutral stance on the stock, suggesting that investors should neither aggressively buy nor sell at this stage. This rating reflects a balanced view of the company’s prospects, considering its strengths and challenges across multiple parameters. The 'Hold' recommendation advises investors to maintain their existing positions while monitoring developments closely.
Quality Assessment
As of 09 June 2026, Shilpa Medicare’s quality grade is assessed as below average. This is primarily due to its modest long-term fundamental strength. The company’s average Return on Capital Employed (ROCE) over recent years stands at 5.44%, which is relatively low for the pharmaceuticals and biotechnology sector. While the company has demonstrated steady growth in net sales at an annual rate of 11.30% and operating profit growth of 19.78% over the last five years, these figures suggest moderate operational efficiency and capital utilisation compared to industry peers.
Valuation Perspective
The valuation grade for Shilpa Medicare is currently classified as expensive. The stock trades at a ROCE of 9.8 and an enterprise value to capital employed ratio of 3.4, indicating a premium valuation relative to its capital base. Despite this, the stock is priced at a discount compared to the average historical valuations of its peers, which may offer some cushion for investors. The company’s PEG ratio of 0.4 further suggests that the stock’s price growth is not fully reflective of its earnings growth potential, signalling a potentially attractive valuation for long-term investors.
Financial Trend and Recent Performance
Financially, Shilpa Medicare exhibits a very positive trend as of 09 June 2026. The company has reported a remarkable 99.09% growth in net profit, with the latest quarterly PAT reaching ₹85.40 crores, representing an 81.2% increase compared to the previous four-quarter average. This strong profitability is supported by the highest quarterly PBDIT of ₹119.71 crores and a half-year ROCE peak of 10.52%. Furthermore, the company has declared positive results for 11 consecutive quarters, underscoring consistent operational improvements and earnings momentum.
Stock returns also reflect this positive trajectory. Over the past year, Shilpa Medicare has delivered a 19.80% return, outperforming the BSE500 index in each of the last three annual periods. The stock’s year-to-date return stands at an impressive 71.72%, with a six-month gain of 64.72% and a three-month surge of 65.38%. These figures highlight strong market confidence and robust price appreciation in recent months.
Technical Outlook
The technical grade for Shilpa Medicare is bullish, indicating positive momentum in the stock’s price action. The recent daily gain of 3.52% and weekly increase of 6.56% reinforce this trend. Technical indicators suggest that the stock is currently in an upward trajectory, which may attract momentum-driven investors. However, given the stock’s expensive valuation and below-average quality grade, investors should weigh technical strength against fundamental considerations.
Shareholding and Market Capitalisation
Shilpa Medicare is classified as a small-cap company within the Pharmaceuticals & Biotechnology sector. The majority of its shares are held by non-institutional investors, which may influence liquidity and trading patterns. Investors should consider this shareholding structure when assessing potential volatility and market behaviour.
Our latest monthly pick, this Small Cap from Oil Exploration/Refineries, is showing strong performance since announcement! See why our Investment Committee chose it after screening 50+ candidates.
- - Investment Committee approved
- - 50+ candidates screened
- - Strong post-announcement performance
What This Rating Means for Investors
The 'Hold' rating for Shilpa Medicare Ltd suggests that investors should adopt a cautious but patient approach. While the company’s recent financial results and technical indicators are encouraging, the below-average quality grade and expensive valuation temper enthusiasm. Investors already holding the stock may consider maintaining their positions to benefit from ongoing earnings growth and positive price momentum. Prospective investors might wait for a more favourable entry point or clearer improvements in fundamental quality before committing fresh capital.
In summary, Shilpa Medicare presents a mixed picture. Its strong recent profitability and bullish technical outlook are offset by modest long-term fundamental strength and a valuation that demands careful scrutiny. The 'Hold' rating reflects this balance, signalling neither a compelling buy opportunity nor a reason for immediate exit.
Sector Context and Comparative Performance
Within the Pharmaceuticals & Biotechnology sector, Shilpa Medicare’s performance is notable for its consistent returns and recent profit acceleration. However, its quality metrics lag behind some larger peers with stronger capital efficiency and growth profiles. The stock’s ability to outperform the BSE500 index over the past three years is a positive indicator of resilience and market positioning. Investors should monitor sector trends, regulatory developments, and competitive dynamics that could impact future performance.
Outlook and Considerations
Looking ahead, Shilpa Medicare’s prospects will depend on sustaining its earnings momentum and improving capital utilisation. The company’s ability to maintain positive quarterly results and expand operating margins will be critical. Valuation levels should be watched closely, especially in relation to peer benchmarks and broader market conditions. Investors are advised to keep abreast of quarterly updates and sector news to reassess the stock’s standing in a timely manner.
Summary of Key Metrics as of 09 June 2026
- Mojo Score: 57.0 (Hold)
- Market Capitalisation: Small Cap
- Return on Capital Employed (5-year average): 5.44%
- Net Sales Growth (5-year CAGR): 11.30%
- Operating Profit Growth (5-year CAGR): 19.78%
- Net Profit Growth (latest quarter): 99.09%
- Quarterly PAT: ₹85.40 crores (81.2% growth vs previous 4Q average)
- Quarterly PBDIT: ₹119.71 crores (highest recorded)
- Half-Year ROCE: 10.52%
- Enterprise Value to Capital Employed: 3.4
- PEG Ratio: 0.4
- Stock Returns: 1Y +19.80%, YTD +71.72%, 6M +64.72%, 3M +65.38%
These figures collectively underpin the current 'Hold' rating, reflecting a stock with promising earnings growth and technical strength but tempered by valuation and quality considerations.
Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year Start at 33% Off →
